Cargando…

Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein (LDL) homeostasis and plays a key role in acute coronary syndrome (ACS). The cardioprotective effect of PCSK9 inhibition extends beyond LDL cholesterol reduction, involving regulation of platelet function by not...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenting, Luo, Ronghua, Pei, Dean, Huang, Qi, Jin, Xinyao, Wu, Yuanhong, Xie, Mingbin, Wang, Shisheng, Sui, Xiangqian, Shen, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101279/
https://www.ncbi.nlm.nih.gov/pubmed/37058054
http://dx.doi.org/10.1097/MD.0000000000033026
_version_ 1785025476023025664
author Wang, Wenting
Luo, Ronghua
Pei, Dean
Huang, Qi
Jin, Xinyao
Wu, Yuanhong
Xie, Mingbin
Wang, Shisheng
Sui, Xiangqian
Shen, Bin
author_facet Wang, Wenting
Luo, Ronghua
Pei, Dean
Huang, Qi
Jin, Xinyao
Wu, Yuanhong
Xie, Mingbin
Wang, Shisheng
Sui, Xiangqian
Shen, Bin
author_sort Wang, Wenting
collection PubMed
description Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein (LDL) homeostasis and plays a key role in acute coronary syndrome (ACS). The cardioprotective effect of PCSK9 inhibition extends beyond LDL cholesterol reduction, involving regulation of platelet function by not yet unraveled mechanisms. Oxidized-LDL (ox-LDL) is increased during ACS and induces platelet activation via binding to platelet surface. We will evaluate serum PCSK9 and its correlation with platelet reactivity and platelet-ox-LDL binding in Chinese ACS patients. METHOD AND DESIGN: In this pilot cross-sectional study, we will enroll 115 Chinese participants aged 30 to 75 years with ACS. Blood sample will be obtained after the first maintenance dose of aspirin and clopidogrel during morning time. Serum PCSK9 will be measured by an enzyme-linked immunoadsorbent assay. Platelet reactivity will be assessed by; Platelet activation (P-selectin and GPIIbIIIa expression using flow cytometry) and; Platelet aggregation using light transmission aggregometry in response to various stimuli. On-treatment platelet reactivity is measured by adenosine diphosphate-induced platelet aggregation. Binding of ox-LDL to platelet will be evaluated by flow cytometry. Spearman correlations will be used to determine association of serum PCSK9 with platelet functional parameters and platelet-ox-LDL binding. Additionally, continuous PCSK9 levels will be categorized into tertiles of equal size to investigate its association with on-treatment platelet reactivity. DISCUSSION: This study will reveal possible relationship between serum PCSK9 and platelet reactivity in the setting of ACS which may shed light on therapeutic potential in platelet inhibition by targeting PCSK9. The study will also explore the association of serum PCSK9 and platelet-ox-LDL binding, an important mechanism for platelet-LDL interplay, to provide mechanistic insight into PCSK9-mediated regulation of platelet reactivity.
format Online
Article
Text
id pubmed-10101279
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101012792023-04-14 Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes Wang, Wenting Luo, Ronghua Pei, Dean Huang, Qi Jin, Xinyao Wu, Yuanhong Xie, Mingbin Wang, Shisheng Sui, Xiangqian Shen, Bin Medicine (Baltimore) 3400 Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein (LDL) homeostasis and plays a key role in acute coronary syndrome (ACS). The cardioprotective effect of PCSK9 inhibition extends beyond LDL cholesterol reduction, involving regulation of platelet function by not yet unraveled mechanisms. Oxidized-LDL (ox-LDL) is increased during ACS and induces platelet activation via binding to platelet surface. We will evaluate serum PCSK9 and its correlation with platelet reactivity and platelet-ox-LDL binding in Chinese ACS patients. METHOD AND DESIGN: In this pilot cross-sectional study, we will enroll 115 Chinese participants aged 30 to 75 years with ACS. Blood sample will be obtained after the first maintenance dose of aspirin and clopidogrel during morning time. Serum PCSK9 will be measured by an enzyme-linked immunoadsorbent assay. Platelet reactivity will be assessed by; Platelet activation (P-selectin and GPIIbIIIa expression using flow cytometry) and; Platelet aggregation using light transmission aggregometry in response to various stimuli. On-treatment platelet reactivity is measured by adenosine diphosphate-induced platelet aggregation. Binding of ox-LDL to platelet will be evaluated by flow cytometry. Spearman correlations will be used to determine association of serum PCSK9 with platelet functional parameters and platelet-ox-LDL binding. Additionally, continuous PCSK9 levels will be categorized into tertiles of equal size to investigate its association with on-treatment platelet reactivity. DISCUSSION: This study will reveal possible relationship between serum PCSK9 and platelet reactivity in the setting of ACS which may shed light on therapeutic potential in platelet inhibition by targeting PCSK9. The study will also explore the association of serum PCSK9 and platelet-ox-LDL binding, an important mechanism for platelet-LDL interplay, to provide mechanistic insight into PCSK9-mediated regulation of platelet reactivity. Lippincott Williams & Wilkins 2023-04-14 /pmc/articles/PMC10101279/ /pubmed/37058054 http://dx.doi.org/10.1097/MD.0000000000033026 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3400
Wang, Wenting
Luo, Ronghua
Pei, Dean
Huang, Qi
Jin, Xinyao
Wu, Yuanhong
Xie, Mingbin
Wang, Shisheng
Sui, Xiangqian
Shen, Bin
Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
title Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
title_full Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
title_fullStr Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
title_full_unstemmed Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
title_short Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
title_sort association of serum pcsk9 levels with platelet function in patients with acute coronary syndromes
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101279/
https://www.ncbi.nlm.nih.gov/pubmed/37058054
http://dx.doi.org/10.1097/MD.0000000000033026
work_keys_str_mv AT wangwenting associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT luoronghua associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT peidean associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT huangqi associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT jinxinyao associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT wuyuanhong associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT xiemingbin associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT wangshisheng associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT suixiangqian associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes
AT shenbin associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes